MANA Pharma follows a hybrid model combining in-house R&D, strategic manufacturing partnerships and external sourcing. This enables us to select the right manufacturing or supply pathway for each product and project, while maintaining a strong focus on quality, documentation and customer requirements.
Successful commercial manufacturing begins with process understanding. We execute the technology and knowledge transfer from development to commercial production, with attention to process parameters, equipment scale-up variables, analytical validation and documentation to ensure long-term batch consistency.
Scale-up requires more than increasing batch size. It requires understanding how equipment, process conditions, raw materials and analytical controls impact product quality and reproducibility. Our development approach considers these factors to deliver reliable, reproducible, and production-ready manufacturing pathways.
For pharmaceutical customers, supplier qualification and audit readiness are essential parts of the sourcing and manufacturing decision. We proactively facilitate customer evaluations by providing comprehensive data on GMP-compliant manufacturing partners, quality systems, regulatory documentation, and technical dossiers, managed securely under robust confidentiality protocols and document-control frameworks.
Our objective is to ensure supply continuity and predictability through optimised manufacturing pathways, cross-functional partner alignment, and rigorous demand planning. Product-specific capacity, scale, lead-time and manufacturing information can be discussed as part of the commercial and technical enquiry process.
Mana Pharma is expanding its manufacturing footprint with an upcoming 10-acre site in Tirupati District. The expansion is intended to strengthen manufacturing capability and support the company's long-term ambition to serve pharmaceutical customers from India to global markets.
DMFs, technical packages and site audit coordination available to qualified partners under confidentiality agreement.